A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer

Trial ID # NCT02345265
Phase II
Drug Class DNA Damage Repair Pathway Inhibitors: PARP
Drug Name Olaparib
Alternate Drug Names AZD2281, Lynparza
Drugs in Trial Cediranib, Olaparib
Eligible Participant

Recurrent high grade serous or high grade endometrioid ovarian cancer

Patients Enrolled

70, 35 Pt-S; median 2 prior therapies

Therapy Setting

Recurrence

Study Design

Open-Label, Non-randomized

Endpoints

ORR, DCR, evaluated per RECIST

Biomarkers

Exploratory: gBRCA1/2

Efficacy

ORR: 74.3% (3CR, 23PR, n=35)
DCR (4 months): 88.6% (3CR, 23PR, 5SD, n=35)

Exploratory analysis gBRCA status:
gBRCA WT: ORR: 83% (10PR, n=12)
gBRCA MUT: ORR: 79% (3CR, 8PR, n=14)

Clinically Significant Adverse Events

Grade 3/4 AE: hypertension (18%)

Conclusion

Olaparib+cediranib is effective independent of gBRCA status

Reference

Liu JF et al. A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca). J Clin Oncol (2018) 36 (suppl; abstr 5519)
https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.5519